Palladone (hydromorphone extended-release capsules) by Woelfel, Joseph A.
University of the Pacific
Scholarly Commons
School of Pharmacy and Health Sciences Faculty
Articles






University of the Pacific, jwoelfel@pacific.edu
Follow this and additional works at: https://scholarlycommons.pacific.edu/phs-facarticles
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the Thomas J. Long School of Pharmacy and Health Sciences at Scholarly Commons. It has
been accepted for inclusion in School of Pharmacy and Health Sciences Faculty Articles by an authorized administrator of Scholarly Commons. For
more information, please contact mgibney@pacific.edu.
Recommended Citation
Woelfel, J. A. (2005). Palladone (hydromorphone extended-release capsules). Pharmacist’s Letter & Prescriber’s Letter, 21(3), 1–4.
https://scholarlycommons.pacific.edu/phs-facarticles/51
 
More. . . 
Copyright © 2005 by Therapeutic Research Center 
Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone:  209-472-2240 ~ Fax:  209-472-2249 








−This Detail-Document accompanies the related article published in− 
PHARMACIST’S LETTER / PRESCRIBER’S LETTER 
March 2005 ~ Volume 21 ~ Number 210308 
 
 
Palladone (Hydromorphone Extended-release Capsules) 
Lead author: Joseph A. Woelfel, Ph.D., FASCP, R.Ph., Assistant Editor 
-Please see Detail-Document #200915 for our updated opioid comparison chart- 
 
What It Is 
Palladone is a new oral extended-release 
hydromorphone product.  It is intended for 
around-the-clock (ATC) administration in opioid-
experienced patients requiring high potency 
analgesia for an extended period of time.  It is the 
first long-acting hydromorphone product available 
in the U.S.  Hydromorphone is a potent opioid mu 
receptor agonist producing analgesia as its 
primary therapeutic action.  Other actions include 
anxiolysis, euphoria, and feelings of relaxation.1 
 
Indications 
Palladone capsules are indicated for the 
management of persistent moderate to severe pain 
in patients requiring continuous ATC high-
potency opioid pain relief for an extended period 
of time ranging from weeks to months or longer.1,2 
It may be used in patients requiring a 
minimum total daily dose of oral opioid therapy 
equivalent to 12 mg of oral hydromorphone.  
These patients must have already received opioid 
therapy and demonstrated opioid tolerance.  
Opioid-tolerant patients are those who are taking 
at least one of the following: 
• 60 mg of oral morphine per day,  
• 30 mg of oral oxycodone per day,  
• 8 mg of oral hydromorphone per day, 
• or any other equianalgesic dose of another 
opioid  
for at least one week.  It is not intended as 
initiation opioid therapy, short term use, or “as 
needed” therapy.1 
 
How Supplied - Cost 
The extended-release Palladone capsules are 
available in 12 mg, 16 mg, 24 mg, and 32 mg 
strengths in bottles of 60 capsules.1,3   
The average wholesale product cost (AWP) 
per capsule is: $7.70/12 mg, $8.99/16 mg, 
$12.95/24 mg, and $16.71/32 mg.3 
 
Product Formulation Considerations 
Palladone capsules contain hydromorphone 
HCl in a pellet formulation which uses a 
controlled-release melt extrusion technology.  
Each pellet contains the same amount of 
hydromorphone with different capsule fill weights 
used to vary strengths.   
It is important to note that demonstrated 
dosage form proportionality on a dose-adjusted 
basis is three 12 mg capsules to one 32 mg 
capsule.1   
The terminal elimination half-life for 
controlled release hydromorphone is 
approximately 18.6 hours.1 
Palladone is formulated for once daily dosing.  
The capsules must not be crushed or altered in any 
way to assure maintenance of pellet integrity. 
Otherwise, rapid-release can result in 
hydromorphone overdose.1   
 
Adverse Effects 
The most frequent adverse events reported in 
placebo-controlled clinical trials with an incidence 
of at least 2% were constipation, nausea, 
headache, somnolence, asthenia, vomiting, and 
pruritus.1   
 
Drug Interactions 
As with other opioid agonists, concomitant 
administration of CNS depressants with Palladone 
may cause respiratory depression, hypotension, 
profound sedation, and may result in coma.  
Hydromorphone combined with skeletal muscle 
relaxants can enhance neuromuscular blockade 
and result in increased respiratory depression.  
Mixed agonist-antagonist opioid analgesics such 
as pentazocine, nalbuphine, and butorphanol 
should be administered with caution due to the 
potential for decreased hydromorphone analgesia 
and precipitation of withdrawal responses.  
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MAOIs should be discontinued at least 14 days 
prior to initiation of Palladone therapy.  
Palladone’s bioavailability is not significantly 
affected by food.1  
 
Contraindications 
Palladone is contraindicated for “as needed” 
therapy, respiratory depression, acute or severe 
bronchial asthma, diagnoses of or suspected 
paralytic ileus, and those hypersensitive to 
hydromorphone or any components in Palladone.1  
 
Precautions and Warnings 
Capsules must not be broken, chewed, opened, 
dissolved, or crushed because of the grave 
potential for fatal overdose.  Palladone must only 
be used in opioid-tolerant patients.  As with all 
CII opioid analgesics, there is increased risk and 
concern about misuse, abuse, addiction, and 
diversion.  In the presence of head injury or 
intracranial lesions, Palladone’s respiratory 
depressant effects may be exaggerated and also 
mask neurological signs of increasing intracranial 
pressure.  Orthostatic hypotension may occur in 
ambulatory patients.  Cautious use of Palladone 
must occur in the presence of pancreatic or biliary 
tract disease.  Palladone must not be used in 
patients with severe hepatic impairment and 
careful dosage selection is recommended for those 
with mild to moderate impairment.  Lower 
dosages should be prescribed in patients with mild 
to moderate renal impairment.  Palladone should 
be used with caution in patients with prior drug or 
alcohol abuse, adrenocortical insufficiency, 
debilitation, myxedema, hypothyroidism, prostatic 
hypertrophy, urethral stricture, and toxic 
psychosis.1 
 
Use in Pregnancy 
Palladone is a Pregnancy Category C drug.  
There are no adequate and well-controlled studies 
in pregnant women.  It should be used only if the 




The dosage of Palladone is dependent on the 
patient’s past opioid experience, tolerance, and 
clinical considerations such as medical condition, 
co-morbidity factors, concomitant therapy, abuse 
history, and past pain control levels.1 
Please see Detail-Document #200915, 
Equianalgesic Dosing of Opioids for Pain 
Management,4 which has been updated to reflect 
Palladone dosing guidance.   
Palladone extended-release capsules should be 
swallowed whole and are administered only once 
daily.  All other ATC opioid products should be 
discontinued when initiating Palladone therapy.  
Patients may need immediate-release medication 
for break-through pain control or for pain 
prevention during certain periods of patient 
activity.  Palladone can be administered with non-
opioid analgesics or other adjuvant therapy as 
long as these are considered when selecting initial 
Palladone dosage.1   
When converting from other opioid analgesics 
to Palladone, monitoring for possible overdose or 
intolerance should occur.  Monitoring for risks 
such as respiratory depression, altered mental 
status, and hypotension are essential.  Because of 
Palladone’s prolonged elimination half-life (18 
hours) overestimation of initial dose requires 
extended monitoring and treatment.1  
 
Manufacturer 
Purdue Pharma L.P. 





Palladone is the first extended-release 
hydromorphone product.  Because of its release 
characteristics it provides dosing at 24 hour 
intervals and must be administered only once 
daily.  It offers an additional choice for opioid-
tolerant patients requiring ATC opioid analgesia.  
Another product, Avinza, is an extended-
release morphine formulation which is also 
administered only once daily at 24 hour intervals.  
Unlike Palladone, Avinza may be prescribed for 
opioid-naïve patients starting at the lowest dose of 
30 mg once-daily.5  Equianalgesic daily doses of 
Palladone will cost slightly more (approximately 
one-third more) than Avinza.3   
Because Palladone is a potent Schedule II 
opioid agonist, it presents a high risk for fatal 
overdose and also potential abuse and diversion.  
Purdue Pharma with the approval of the FDA has 
a patient Medication Guide which must be 
dispensed with each Palladone prescription.  It is 
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The following excerpts are reprinted from the 
September 24, 2004 FDA Talk Paper concerning FDA 
approval of Palladone and the development of an 
effective plan to reduce inappropriate use: 
http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01
315.html.   
 
 
The active ingredient in Palladone, 
hydromorphone, is currently a Schedule II 
controlled substance, which is the highest level of 
control for drugs with a recognized medical use. 
Based on the risks associated with the drug, 
including the potential for abuse of Palladone, 
FDA has worked with the sponsor to develop a 
comprehensive risk management program (RMP).  
The RMP was designed with three potential 
risk situations identified.  These are the risks 
posed by improper dosing, indication, or patient 
selection; the risk posed by accidental pediatric 
exposure to the drug; and the risk posed by abuse 
or diversion of Palladone capsules.  
As a controlled substance in Schedule II of the 
Controlled Substances Act (CSA), Palladone also 
comes under the jurisdiction of the Drug 
Enforcement Administration (DEA), which 
administers the CSA.  Schedule II drugs are 
subject to manufacturing quotas set by DEA with 
input on medical need from FDA, distribution 
tracking, import and export controls, registration 
of prescribers and dispensers, and written 
prescriptions without refills.  
In addition to the protection afforded patients 
through the status of Palladone as a controlled 
substance, the RMP includes provisions for clear 
and appropriate labeling, and appropriate 
education of healthcare professionals, patients, 
and caregivers.  In addition, the sponsor has 
committed to offer appropriate training to sales 
representatives.  To guard against the 
inappropriate use of the drug, the RMP also 
establishes a multifaceted program for monitoring 
and surveillance of abuse. If abuse, misuse, and 
diversion occur, the program includes an array of 
interventions.  
As part of the RMP, a Medication Guide 
(FDA-approved patient information which is 
required to be dispensed with each prescription) 
has been written for patients prescribed 
Palladone.  FDA requires a Medication Guide 
only when one or more of the following 
circumstances exists: (1) the drug is one for which 
patient labeling could help prevent serious adverse 
effects; (2) the drug is one that has serious risks of 
which patients should be made aware because 
information concerning the risks could affect 
patients' decision to use, or continue to use the 
drug; and (3) the drug is important to health and 
patient adherence to directions for use is crucial to 
the drug's effectiveness. In addition, the physician 
labeling for Palladone contains a “black box” 
warning.  
FDA is also part of a larger initiative to reduce 
diversion and abuse of prescription drugs. On 
March 1, 2004, the Office of National Drug 
Control Policy was joined by the Surgeon 
General, the DEA Administrator, and the FDA 
Commissioner to announce the National Drug 
Control Strategy.  The strategy emphasized new 
collaborative efforts at the federal, state, and local 
levels to prevent and reduce diversion and abuse 
of prescription drugs.  This strategy focused on 
three core tactics: (1) Business Outreach and 
Consumer Protection, (2) Investigation and 
Enforcement, and (3) Protecting Safe and 
Effective Use of Medications.  During the 
approval process for Palladone, FDA 
incorporated many of the elements of this strategy 
as exhibited by inclusion of the “black box” 
warnings on the labeling, the Medication Guide, 





Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
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